Understanding the Market | Junshi Biosciences rose over 4% as the net loss attributable to the parent company in the first three quarters narrowed by 35.7% year-on-year, with strong sales performance of Tuoyi®
Junshi Biosciences rose over 4%, as of the time of writing, up 3.99%, priced at HKD 26.06, with a transaction volume of HKD 59.4286 million. In terms of news, on October 28th, Junshi Biosciences announced that for the first three quarters of 2025, operating revenue was RMB 1.806 billion, a year-on-year increase of 42.06%; the net loss attributable to shareholders of the listed company was RMB 596 million, a year-on-year narrowing of 35.7%; basic loss per share was RMB 0.60. The announcement stated that the growth in operating revenue during the period was mainly due to the increase in sales revenue from commercialized drugs, among which the core product Toripalimab injection (trade name: Tuoyi®/LOQTORZI®, product code: JS001) achieved sales revenue of approximately RMB 1.495 billion in the domestic market, a year-on-year increase of about 40%. At the same time, the company continues to implement the "Quality Improvement, Efficiency Enhancement, and Return Focus" action plan, strengthening expense control and resource focus, with the loss amount significantly narrowing compared to the same period last year. As of the end of the reporting period, the company's cash and cash equivalents and trading financial assets totaled RMB 3.270 billion, indicating a relatively sufficient capital reserve
According to the Zhitong Finance APP, Junshi Biosciences (01877) rose over 4%, and as of the time of publication, it was up 3.99%, trading at HKD 26.06, with a transaction volume of HKD 59.4286 million.
In terms of news, on October 28, Junshi Biosciences announced that for the first three quarters of 2025, the operating revenue was RMB 1.806 billion, a year-on-year increase of 42.06%; the net loss attributable to shareholders of the listed company was RMB 596 million, a year-on-year narrowing of 35.7%; the basic loss per share was RMB 0.60.
The announcement stated that the growth in operating revenue during the period was mainly driven by the increase in sales revenue from commercialized drugs, among which the core product Toripalimab injection (brand name: Tuoyi®/LOQTORZI®, product code: JS001) achieved sales revenue of approximately RMB 1.495 billion in the domestic market, a year-on-year increase of about 40%. At the same time, the company continues to implement the "improving quality and efficiency, focusing on returns" action plan, strengthening cost control and resource focus, with the loss amount significantly narrowing compared to the same period last year. As of the end of the reporting period, the company's cash and trading financial assets totaled RMB 3.270 billion, indicating a relatively sufficient capital reserve
